a public good project by the
Synthesis
Company
of California

© 2026

M. Diago | doi.page

0 works0 citations0 h-index

M. Diago

Universitat de València(ES)Hospital General Universitario De Valencia(ES)

Publications by Year

Research Areas

Hepatitis C virus research, Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, Systemic Lupus Erythematosus Research, HIV/AIDS drug development and treatment

Most-Cited Works

→ Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection(2002)6,389 cited
→ Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis(2015)2,336 cited
→ Telaprevir for Retreatment of HCV Infection(2011)1,534 cited
→ Peginterferon Alfa-2a in Patients with Chronic Hepatitis C(2000)1,224 cited
→ Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B(2004)1,136 cited
→ Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients(2005)733 cited
→

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin

(2005)

517 cited

→ Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment(2006)360 cited

→ A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin(2010)324 cited

→ Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B(2006)262 cited